Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bower

Showing results (131-140 of 252) with videos related to

Pageof 26
Sort By:
The Journal of Antimicrobial Chemotherapy|May 25, 2005
Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterolVictoria Latham, Justin Stebbing, Sundhiya Mandalia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Clinical Features and Outcome in HIV-Associated Multicentric Castleman's DiseaseMark Bower, Tom Newsom-Davis, Kikkeri Naresh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2011
The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapyLaura J Waters, Andrew T Scourfield, Marie Marcano, et al.
AIDS (London, England)|December 18, 2024
Haemophagocytic lymphohistiocytosis in HIV-associated HHV-8-positive multicentric Castleman diseasePascal Migaud, Alessia Dalla Pria, Kai Hosmann, et al.
Blood|April 23, 2011
Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman diseaseJustin Stebbing, Caroline Adams, Adam Sanitt, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?Mark Bower, Tom Powles, Tom Newsom-Davis, et al.
Oncoimmunology|September 19, 2017
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot studySalvinia Mletzko, David J Pinato, Rebecca C Robey, et al.
International Journal of Cancer|December 4, 2003
Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcomaJustin Stebbing, Brian Gazzard, Tom Newsom-Davis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2011
Combination antiretroviral therapy toxicities: a comparison between patients and health care professionalsMark Nelson, Stuart Yau, Laura Baber, et al.
AIDS Research and Human Retroviruses|August 28, 2012
Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral loadJohn N S Gregson, Leticia Kuri-Cervantes, Christopher M Mela, et al.
Pageof 26

Showing results (131-140 of 252) with videos related to

Sort By:
Pageof 26
The Journal of Antimicrobial Chemotherapy|May 25, 2005
Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterolVictoria Latham, Justin Stebbing, Sundhiya Mandalia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Clinical Features and Outcome in HIV-Associated Multicentric Castleman's DiseaseMark Bower, Tom Newsom-Davis, Kikkeri Naresh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 5, 2011
The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapyLaura J Waters, Andrew T Scourfield, Marie Marcano, et al.
AIDS (London, England)|December 18, 2024
Haemophagocytic lymphohistiocytosis in HIV-associated HHV-8-positive multicentric Castleman diseasePascal Migaud, Alessia Dalla Pria, Kai Hosmann, et al.
Blood|April 23, 2011
Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman diseaseJustin Stebbing, Caroline Adams, Adam Sanitt, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?Mark Bower, Tom Powles, Tom Newsom-Davis, et al.
Oncoimmunology|September 19, 2017
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot studySalvinia Mletzko, David J Pinato, Rebecca C Robey, et al.
International Journal of Cancer|December 4, 2003
Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcomaJustin Stebbing, Brian Gazzard, Tom Newsom-Davis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 26, 2011
Combination antiretroviral therapy toxicities: a comparison between patients and health care professionalsMark Nelson, Stuart Yau, Laura Baber, et al.
AIDS Research and Human Retroviruses|August 28, 2012
Short communication: NKG2C+ NK cells contribute to increases in CD16+CD56- cells in HIV type 1+ individuals with high plasma viral loadJohn N S Gregson, Leticia Kuri-Cervantes, Christopher M Mela, et al.
Pageof 26